The number of cases of severe dengue disease continues to grow in endemic areas of
southeast Asia, Central and South America, and other subtropical regions. Children bear the …

Dengue has become the most rapidly expanding mosquito-borne infectious disease on the
planet, surpassing malaria and infecting at least 390 million people per year. There is no …

Zika virus, influenza, and Ebola have called attention to the ways in which infectious disease
outbreaks can severely – and at times uniquely – affect the health interests of pregnant …

… Dr Durbin reported receiving grants from Pfizer as an investigator for the Pfizer COVID-19
vaccine trial and grants from NIH for serving as the site principal investigator for the …

Background Pfs25 and Pvs25, surface proteins of mosquito stage of the malaria parasites P.
falciparum and P. vivax, respectively, are leading candidates for vaccines preventing …

Apical membrane antigen 1 (AMA1), a polymorphic merozoite surface protein, is a leading
blood-stage malaria vaccine candidate. A phase 1 trial was conducted with 30 malaria-…

… Sequence analysis showed that the wt 814669 virus used in this study had apparently
accumulated two missense mutations (nucleotides 5826 and 7630) and three silent mutations …

… We report the first phase 1 clinical trial of a P. vivax transmission blocking vaccine in humans.
The Pvs25H vaccine is a recombinant protein derived from the Pvs25 surface antigen of P. …

In vitro studies have attempted to identify dengue virus (DEN) target cells in peripheral blood;
however, extensive phenotyping of peripheral blood mononuclear cells (PBMCs) from …

Background. The 4 serotypes of dengue virus, DENV-1–4, are the leading cause of arboviral
disease globally. The ideal dengue vaccine would provide protection against all serotypes …